 This is an open-label, sequential enrollment study characterizing the pharmacodynamic PD, pharmacokinetic PK and safety of HSP-130 in subjects with non-metastatic breast cancer who have not previously received chemotherapy at any point prior to enrollment in this study ZIN-130-1504. 